This book is intended solely as a work of reference on the history and possible future of medicine. It should not be referred to for advice or guidance on the diagnosis, treatment or prognosis of any medical condition. In case of illness, consult your doctor.
THE THIRTEENTH EDITION OF THE CLASSIC TEXTBOOK, FIRST PUBLISHED IN 1960 Written by one of the great teachers of anatomy, the thirteenth edition of Clinical Anatomy continues to provide thousands of medical students, postgraduate trainees and junior doctors across the world with essential anatomical information within a clinical setting. It is particularly appropriate for those preparing for the Intercollegiate Membership Examination of the Royal Colleges of Surgeons (I-MRCS). Professor Harold Ellis is again joined by Professor Vishy Mahadevan to provide detailed, easy-to-follow structured text suitable for anatomy students and trainees of all levels. Fully revised and updated with many new illustrations, this new edition features for the first time, several anatomical drawings overlaid on a living anatomy model to provide detailed topographical orientation and accurate surface representation. The companion website at www.ellisclinicalanatomy.co.uk/13edition contains digital flashcards of all the illustrations and photographs contained in the book – ideal for revision and teaching purposes.
The primary aim of this report is to share survey and surveillance data on drug resistance in tuberculosis (TB). The data presented here are supplied largely by the programme managers who have led the work on surveys, but also by heads of reference laboratories and by principal investigators who may have been hired to assist the national TB programmes with the study. We thank all of them, and their staff, for their contributions. The World Health Organization/International Union Against Tuberculosis and Lung Disease (WHO/UNION) Global Project on Anti-Tuberculosis Drug Resistance Surveillance is carried out with the financial backing of United States Agency for International Development (USAID) and Eli Lilly and Company as part of the Lilly multidrug resistant (MDR)-TB Partnership. Drug resistance surveys were supported financially by the Dutch Government, the Global Fund, Japan International Cooperation Agency (JICA), Kreditanstalt für Wiederaufbau (KfW Entwicklungsbank), national TB programmes and USAID). The Supranational Reference Laboratory Network provided the external quality assurance, as well as technical support to many of the countries reporting. Technical support for surveys was provided by the Centers for Disease Control and Prevention (CDC), JICA, the Royal Netherlands Tuberculosis Association (KNCV), and WHO. Data for the WHO European Region were collected and validated jointly with EuroTB (Paris) — a European TB surveillance network funded by the European Commission.